Dianthus Therapeutics (NASDAQ:DNTH) Hits New 1-Year High - Here's What Happened

Key Points

• Dianthus Therapeutics' stock hit a new 52-week high, reaching $39.22 during trading, and currently has a market cap of $1.26 billion.
• Multiple analysts have upgraded their ratings for the company, with price targets raised significantly, including Robert W. Baird increasing it to $67.00 and Guggenheim raising it to $100.00.
• The company recently reported a quarterly loss of ($0.88) earnings per share, missing analyst estimates, alongside a revenue of $0.19 million compared to expectations of $0.87 million.

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) hit a new 52-week high on Wednesday . The stock traded as high as $39.22 and last traded at $39.18, with a volume of 87083 shares traded. The stock had previously closed at $37.47.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Wedbush upped their target price on Dianthus Therapeutics from $42.00 to $44.00 and gave the stock an "outperform" rating in a report on Friday, September 12th. Stifel Nicolaus upped their target price on Dianthus Therapeutics from $52.00 to $65.00 and gave the stock a "buy" rating in a report on Friday, September 12th. Raymond James Financial reiterated an "outperform" rating and issued a $63.00 target price (up from $56.00) on shares of Dianthus Therapeutics in a report on Tuesday, September 9th. Robert W. Baird upped their target price on Dianthus Therapeutics from $50.00 to $67.00 and gave the stock an "outperform" rating in a report on Tuesday, September 9th. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday, September 8th. Nine equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $61.57.

Dianthus Therapeutics Price Performance

The firm has a fifty day simple moving average of $24.83 and a 200 day simple moving average of $21.12. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -11.31 and a beta of 1.46.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. The business had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.87 million. Research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Insider Activity

In other news, CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total value of $700,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 8.15% of the stock is owned by corporate insiders.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors have recently made changes to their positions in DNTH. Vestal Point Capital LP lifted its position in Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock worth $59,616,000 after buying an additional 1,499,931 shares in the last quarter. RA Capital Management L.P. grew its stake in shares of Dianthus Therapeutics by 53.6% in the first quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company's stock valued at $52,003,000 after buying an additional 1,000,333 shares in the last quarter. Candriam S.C.A. acquired a new position in Dianthus Therapeutics during the 1st quarter worth $4,510,000. Octagon Capital Advisors LP grew its stake in Dianthus Therapeutics by 11.0% during the 1st quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company's stock worth $42,478,000 after purchasing an additional 231,500 shares in the last quarter. Finally, Alliancebernstein L.P. grew its stake in Dianthus Therapeutics by 14.5% during the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company's stock worth $21,887,000 after purchasing an additional 149,200 shares in the last quarter. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.